Therapeutic Potential of Cilostazol in Aneurysmal Subarachnoid Hemorrhage: A Systematic Review

Felicia Felicia, Michael Jaya

Abstract


Introduction: Vasospasm and delayed cerebral infarction (DCI) are factors that influence the prognosis and clinical outcomes in subarachnoid hemorrhage (SAH). Although several pharmacological therapies are considered potentially effective in reducing vasospasm and DCI, only a few have shown significant benefits. This systematic review aims to evaluate the therapeutic benefits of cilostazol in patients with aneurysmal subarachnoid hemorrhage (aSAH).
Subject and Methods: A systematic search was conducted on studies from January 2009 to March 2024 across five databases, guided by PRISMA 2021. The outcomes evaluated may include angiographic vasospasm, symptomatic vasospasm, the severity of vasospasm, new cerebral infarctions, delayed cerebral ischemia, and functional outcomes.
Results: Following analysis, 9 studies were included in this systematic review, involving 627 patients in the cilostazol group and 631 patients in the control group. Most of these studies indicated that cilostazol administration in SAH yielded positive effects on cerebral vasospasm, new infarctions, and functional outcomes. However, there was no evidence to support the effectiveness of cilostazol in preventing DCI.
Conclusion: Overall, cilostazol appears to be a promising therapy for SAH. However, the impact of cilostazol on DCI warrants further investigation, possibly due to the complex mechanisms of DCI.


Keywords


Cerebral infarct, cilostazol, subarachnoid hemorrhage, vasospasm

Full Text:

PDF

References


Sanicola HW, Stewart CE, Luther P, Yabut K, Guthikonda B, Jordan JD, Alexander JS. Pathophysiology, management, and therapeutics in subarachnoid hemorrhage and delayed cerebral ischemia: An overview. pathophysiology. 2023;30(3):420–42. Doi: 10.3390/pathophysiology30030032

Dayyani M, Sadeghirad B, Grotta JC, Zabihyan S, Ahmadvand S, Wang Y, et al. Prophylactic therapies for morbidity and mortality after aneurysmal subarachnoid hemorrhage: A systematic review and network meta-analysis of randomized trials. Stroke. 2022;53(6):1993–2005. Doi: 10.1161/STROKEAHA.121.035699

Luong CQ, Ngo HM, Hoang HB, Pham DT, Nguyen TA, Tran TA, et al. Clinical characteristics and factors relating to poor outcome in patients with aneurysmal subarachnoid hemorrhage in Vietnam: A multicenter prospective cohort study. PLoS One. 2021;16(8): 1–18. Doi: 10.1371/journal.pone.0256150.

Yu W, Huang Y, Zhang X, Luo H, Chen W, Jiang Y, et al. Effectiveness comparisons of drug therapies for postoperative aneurysmal subarachnoid hemorrhage patients: network meta analysis and systematic review. BMC Neurol. 2021;21(1): 1–13. Doi: 10.1186/s12883-021-02303-8

Chousterman B, Leclère B, Morisson L, Eude Y, Gayat E, Mebazaa A, et al. A network meta-analysis of therapeutic and prophylactic management of vasospasm on aneurysmal subarachnoid hemorrhage outcomes. Frontiers in Neurology. 2023;14:1–8. Doi: https://doi.org/10.3389/fneur.2023.1217719

Veldeman M, Höllig A, Clusmann H, Stevanovic A, Rossaint R, Coburn M, et al. Delayed cerebral ischaemia prevention and treatment after aneurysmal subarachnoid haemorrhage: A systematic review. Br J Anaesth. 2016;117(1):17–40. Doi: 10.1093/bja/aew095.

Senbokuya N, Kinouchi H, Kanemaru K, Ohashi Y, Fukamachi A, Yagi S, et al. Effects of cilostazol on cerebral vasospasm after aneurysmal subarachnoid hemorrhage: A multicenter prospective, randomized, open-label blinded end point trial - Clinical article. J Neurosurg. 2013;118(1):121–30. Doi: 10.3171/2012.9.JNS12492

Lee KS, Lee C, Dhillon PS, Kirollos R, Nga VDW, Yeo TT, et al. Antiplatelet therapy in aneurysmal subarachnoid hemorrhage: an updated meta-analysis. Neurosurg Rev. Springer Science and Business Media Deutschland GmbH; 2023;46(1):1–11 . Doi: 10.1007/s10143-023-02120-2

Nishino A, Umegaki M, Fujinaka T, Yoshimine T. Cilostazol attenuates cerebral vasospasm after experimental subarachnoid hemorrhage. Neurol Res. 2010;32(8):873-8. doi: 10.1179/016164109X12608733393791.

Suzuki S, Sayama T, Nakamura T, Nishimura H, Ohta M, Inoue T, et al. Cilostazol improves outcome after subarachnoid hemorrhage: A preliminary report. Cerebrovasc Dis. 2011;32(1):89–93. Doi: 10.1159/000327040

Matsuda N, Naraoka M, Ohkuma H, Shimamura N, Ito K, Asano K, et al. Effect of cilostazol on cerebral vasospasm and outcome in patients with aneurysmal subarachnoid hemorrhage: A randomized, double-blind, placebo-controlled trial. Cerebrovasc Dis [Internet]. 2016 Jun 1 [cited 2024 Feb 24];42(1–2):97–105. Available from: https://pubmed.ncbi.nlm.nih.gov/27070952/

Sugimoto K, Nomura S, Shirao S, Inoue T, Ishihara H, Kawano R, et al. Cilostazol decreases duration of spreading depolarization and spreading ischemia after aneurysmal subarachnoid hemorrhage. Ann Neurol [Internet]. 2018 Dec 1 [cited 2024 Feb 24];84(6):873–85. Available from: https://pubmed.ncbi.nlm.nih.gov/30341966/

Yoshimoto T, Shirasaka T, Fujimoto S, Yoshidumi T, Yamauchi T, Tokuda K, et al. Cilostazol may prevent cerebral vasospasm following subarachnoid hemorrhage. Neurol Med Chir (Tokyo). 2009; 49(6):235-40; discussion 240–1. Doi: 10.2176/nmc.49.235

Kimura H, Okamura Y, Chiba Y, Shigeru M, Ishii T, Hori T, et al. Cilostazol administration with combination enteral and parenteral nutrition therapy remarkably improves outcome after subarachnoid hemorrhage. Acta Neurochir Suppl. 2014;120:147–52. Doi: 10.1007/978-3-319-04981-6_25

Nakajima H, Okada T, Kawakita F, Oinaka H, Suzuki Y, Nampei M, et al. Cilostazol may improve outcomes even in patients with aneurysmal subarachnoid hemorrhage aged 75 years and older: Multicenter cohort study and propensity score–matched analyses. World Neurosurg. 2024181:e273-e290. doi: 10.1016/j.wneu.2023.10.039.

Kim KH, Lee BJ, Koo HW. Effect of cilostazol on delayed cerebral infarction in aneurysmal subarachnoid hemorrhage using explainable predictive modeling. Bioengineering. 2023;10(7):1–14. Doi: 10.3390/bioengineering10070797

Nishikawa Y, Yamada S, Uchida M, Yamanaka T, Hayashi Y, Katano H, et al. Japanese nationwide questionnaire survey on delayed cerebral infarction due to vasospasm after subarachnoid hemorrhage. Front Neurol. 2023;14. Doi: https://doi.org/10.3389/fneur.2023.1296995

Snyder MH, Ironside N, Kumar JS, Doan KT, Kellogg RT, Provencio JJ, et al. Antiplatelet therapy and delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. J Neurosurg. 2021; 137(1): 95–107. Doi: https://doi.org/10.3171/2021.7.jns211239

Kanamaru H, Kawakita F, Asada R, Miura Y, Shiba M, Toma N, et al. Prognostic factors varying with age in patients with aneurysmal subarachnoid hemorrhage. J Clin Neurosci. 2020;76:118–25. 76:118-125. Doi: 10.1016/j.jocn.2020.04.022

Hoh BL, Ko NU, Amin-Hanjani S, Hsiang-Yi Chou S, Cruz-Flores S, Dangayach NS, et al. 2023 Guideline for the management of Patients with aneurysmal subarachnoid hemorrhage: A guideline from the American Heart Association/American Stroke Association. Stroke. 2023;54(7):E314–70. Doi: https://doi.org/10.1161/STR.0000000000000436




DOI: https://doi.org/10.24244/jni.v14i2.613

Refbacks

  • There are currently no refbacks.


                                    

 

JNI is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License